BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

March 31, 2011

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Type 2 Diabetes

Interventions

DRUG

Saxagliptin

Tablet, Oral, 5 mg, once on Day 1 only

DRUG

Metformin XR

Tablet, Oral, 500 mg, once on Day 1 only

DRUG

Saxagliptin/Metformin XR FDC

Tablet, Oral, 5/500 mg, once on Day 1 only

Trial Locations (1)

Local Institution, Campinas